论文部分内容阅读
肺癌的发病率在世界范围逐年上升,在我国肺癌已占常见肿瘤第1位。其中非小细胞肺癌占肺癌的80%左右,首诊时多属晚期,能够作为根治性手术者仅占30%左右。因而化疗是晚期非小细胞肺癌多学科治疗的主要策略之一。其中以铂类为基础的联合化疗效果优于最佳支持治疗,也能达到减轻症状、提高生活质量和延长生存期的目的。目前在对于DNA损伤修复基因的研究中发现,切除修复交叉互补基因1与非小细胞肺癌铂类化疗敏感性及其预后有关,本文对其研究进展进行综述。
The incidence of lung cancer increased year by year in the world, lung cancer in China has accounted for the first common tumor. Of which non-small cell lung cancer accounts for about 80% of lung cancer, the first diagnosis is mostly late, can only as a radical surgery accounted for about 30%. Chemotherapy is therefore one of the main strategies for multidisciplinary treatment of advanced non-small cell lung cancer. Which platinum-based combination chemotherapy is better than the best supportive treatment, but also can achieve the purpose of alleviating symptoms, improving quality of life and prolonging survival. Currently in the study of DNA damage repair genes found that resection and repair of cross-complementary gene 1 and non-small cell lung cancer platinum sensitivity and prognosis of platinum-related research in this article are reviewed.